Both trimetazidine (i.e., trimetazidine hydrochloride) and isosorbide mononitrate have optimal indications, and it is not possible to compare which is better because of differences in emphasis. Trimetazidine hydrochloride is indicated for use in adult patients with unstable angina who have poor control of first-line antianginal therapy. It should be contraindicated in persons who are hypersensitive to the product, in persons with severe renal impairment, and in patients with tremor, restless legs syndrome, Parkinson’s disease, Parkinson’s syndrome, and other associated movement disorders. Isosorbide mononitrate is suitable for long-term treatment of coronary heart disease, prevention of angina pectoris, treatment of persistent angina pectoris after myocardial infarction, and can also be used in combination with digitalis and/or diuretics for the treatment of chronic heart failure. It should be prohibited for use in people who are allergic to the product, people with severe hypotension, people in a state of shock, people with multiple heart diseases, and people who use sildenafil in combination. Adverse drug reactions to trimetazidine hydrochloride are common dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash, itching, urticaria, weakness. Adverse drug reactions to isosorbide mononitrate include headache, facial flushing, vertigo, reflex tachycardia, and upright hypotension. Trimetazidine hydrochloride and isosorbide mononitrate both have antimyocardial ischemic effects, but the bias of angina indications is different, with the former being more suitable for add-on therapy in the case of poor or intolerant conventional drug therapy, and the latter being more suitable for longer-term therapy as well as co-administration in chronic heart failure. The two drugs are not comparable, and the more appropriate drug treatment should be chosen under the guidance of a physician, and should not be used without authorization.